Chronic NSAID Use Undermines TRPV1-Mediated Longevity by Disrupting Microbiota-Dependent Bile Acid-FXR Signaling

Hypothesis

Chronic NSAID administration abolishes the lifespan‑extending and metabolic benefits observed in TRPV1‑deficient mice by remodeling the gut microbiome in a way that reduces bile‑salt hydrolase (BSH) activity, lowering secondary bile acid production and thereby weakening intestinal FXR signaling.

Mechanistic Basis

• TRPV1 deletion lowers CGRP release from pancreatic sensory neurons, enhancing insulin secretion and promoting longevity [1].
• NSAIDs inhibit cyclooxygenase, altering prostaglandin‑driven gut motility and secretion, which shifts microbial communities toward taxa with low BSH expression (e.g., ↑Blautia, ↓Bifidobacterium) [2].
• Reduced BSH activity decreases conversion of primary to secondary bile acids such as deoxycholic acid, diminishing FXR activation in ileal enterocytes and hepatocytes [3].
• Weak FXR signaling compromises intestinal barrier integrity, increases hepatic inflammation, and promotes cellular senescence, offsetting the metabolic improvements from TRPV1/CGRP modulation.

Thus, the net effect of chronic NSAID use is a microbiome‑mediated "aged" bile acid profile that overrides any direct analgesic benefit.

Testable Predictions

1. Lifespan assay – Old wild‑type mice receiving chronic ibuprofen (or another NSAID) will show no survival advantage compared to untreated controls, whereas TRPV1‑KO mice treated with the same NSAID will lose their extended lifespan relative to NSAID‑free TRPV1‑KO littermates.
2. Metabolic read‑outs – NSAID‑treated TRPV1‑KO mice will exhibit higher fasting glucose, lower insulin sensitivity, and elevated hepatic TNF‑α levels compared with NSAID‑free TRPV1‑KO mice.
3. Microbiome and bile acids – 16S rRNA sequencing will reveal NSAID‑induced increases in Blautia and decreases in Bifidobacterium; metabolomics will show reduced secondary bile acid pools and a higher primary/secondary bile acid ratio.
4. Rescue experiment – Co‑administration of a FXR agonist (e.g., obeticholic acid) or supplemental deoxycholic acid to NSAID‑treated TRPV1‑KO mice will restore intestinal FXR target gene expression (Fgf15, Shp), improve barrier function (zonulin‑1, occludin), and rescue both metabolic health and lifespan extension.
5. Microbiota transfer – Fecal microbiota transplantation from NSAID‑treated donors into germ‑free TRPV1‑KO recipients will recapitulate the bile acid shift and shorten lifespan, confirming causality.

Potential Confounders and Controls

• NSAID‑induced gastrointestinal bleeding could independently affect health; use low‑dose, chronic regimens that avoid ulceration and monitor for occult blood.
• Off‑target effects of NSAIDs on prostaglandin signaling in pancreatic cells; include a group receiving a selective COX‑2 inhibitor to isolate microbiome effects.
• Ensure all mice are housed under identical SPF conditions and that diet is standardized to prevent confounding bile acid variations.

Summary

If chronic NSAID use disrupts the microbiota‑BSH‑FXR axis, it will negate the longevity‑promoting actions of TRPV1/CGRP signaling. Demonstrating this interaction would reframe analgesic safety profiles and suggest microbiome‑targeted or FXR‑based co‑therapies to preserve the healthspan benefits of pain pathway modulation.